IMI – Innovative Medicines Initiative: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets
COMPACT represents Europe’s frontrunners in pharmaceutical sciences, nanotechnology, biology, chemistry, engineering and bio-imaging who will work on the challenges of biopharmaceuticals delivery. The main objectives are to identify and understand transport pathways across major biological barriers and cell membranes that can be harnessed for delivery of biopharmaceuticals, and to construct, characterise and pre-clinically validate novel formulations of biopharmaceuticals for their non-invasive delivery with an emphasis on oral, airway and (trans)dermal routes of administration and for transport across the blood brain barrier after systemic administration. This will be achieved by setting up sophisticated in vitro models of biological barriers and appropriate animal models to identify and exploit novel cell pathways for effective delivery of biopharmaceuticals. In parallel, COMPACT will alter the biopharmaceuticals either by chemical or biological engineering or by nano-formulations to enhance their cellular uptake or transport over biological barriers. To be able to follow the transport and stability in the various stages of the delivery process, advanced imaging techniques will be utilised.
The unique feature of this consortium is the alliance of experts in different research fields that complement each other in this challenging task. It is only the concerted action of such an interdisciplinary consortium that can make a difference in finding constructive solutions to the problem of poor bioavailability and targeted accessibility of biopharmaceuticals.
The COMPACT team, coordinated by Sanofi, GSK and Universiteit Utrecht is working on finding ways to bring biopharmaceuticals to their target while preserving their effectiveness. The five year scientific program will deliver:
- Detailed elucidation of cellular uptake and processing mechanisms;
- Understanding of variables which determine distribution of biological macromolecules in tissues;
- Organ and tissue specific nanotechnology-based delivery methods for biological macromolecules; and
- Delivery strategies for biological macromolecules via local and non-injectable application routes.
COMPACT participants are Sanofi-Aventis Deutschland GmbH, Universiteit Utrecht, University of Copenhagen - Faculty of Health and Medical Sciences, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Cardiff University, Stockholms Universitet, Norges Teknisk- Naturvitenskapelige Universitet NTNU, Universität Wien, Ludwig-Maximilians-Universität München, Universitaet Zürich, Universiteit Gent, Pharmacoidea Development and Service Ltd, Bioneer A/S, Helsingin Yliopisto, Universiteit Leiden, The Chancellor, Masters and Scholars of the University of Oxford, Glaxosmithkline research & development ltd, AbbVie Deutschland GmbH & Co. KG, Novo Nordisk A/S, Merck KGaA, Boehringer Ingelheim International GmbH, Pfizer Limited.
For further details – please visit: www.compact-research.org